Cbl-b predicts postoperative survival in patients with resectable pancreatic ductal adenocarcinoma
Metrics: PDF 710 views | HTML 1079 views | ?
Qian Dong1, Yuteng Ma2, Yao Zhang3, Xiujuan Qu4, Zhi Li4, Yafei Qi5, Yunpeng Liu4, Ce Li4, Kai Li1, Xianghong Yang5 and Xiaofang Che4
1Department of Oncology, Shengjing Hospital of China Medical University, Shenyang 110004, China
2Department of Gastrointestinal Surgery, Peking University Cancer Hospital, Beijing 100142, China
3Department of Ultrasound, Shengjing Hospital of China Medical University, Shenyang 110004, China
4Department of Medical Oncology, The First Hospital of China Medical University, Shenyang 110001, China
5Department of Pathology, Shengjing Hospital of China Medical University, Shenyang 110004, China
Xianghong Yang, email: firstname.lastname@example.org
Xiaofang Che, email: email@example.com
Keywords: pancreatic ductal adenocarcinoma (PDAC), Cbl-b, prognosis
Received: January 01, 2017 Accepted: May 21, 2017 Published: June 27, 2017
Casitas B-lineage lymphoma b (Cbl-b) is a ubiquitin-protein ligase and a signal transducing adaptor protein involved in immune regulation, and it may be involved in the development and progression of cancer. We investigated the association between Cbl-b expression and prognosis in patients with resectable pancreatic ductal adenocarcinoma (PDAC). The clinicopathological characteristics and survival data of 134 patients with surgery for PDAC between January 2009 and February 2012 were retrospectively evaluated, and Cbl-b expression was assayed by immunohistochemical staining. The association of Cbl-b expression with clinicopathological features and postoperative prognosis was analyzed. Cbl-b expression was strongly associated with the pathological primary tumor (pT) category (P = 0.005) and pathological TNM (pTNM) stage (P = 0.035), but not with other clinicopathological characteristics (all P > 0.05). In addition to current markers including pathological regional lymph nodes (pN) category, CA19-9, and histological differentiation, univariate and multivariate analysis found that Cbl-b was independently associated with overall survival (OS) of patients with resectable PDAC. Cbl-b was predictive of OS in a subgroup of patients with serum CA19-9 ≥ 37 U/mL. Cbl-b expression combined with pN, histological differentiation, and CA19-9 level could be used as a novel clinical model predictive of OS for patients with resectable PDAC. In conclusion, Cbl-b in resectable PDAC was an independent predictor of adverse prognosis. Cbl-b expression together with pN, histological differentiation, and CA19-9 level might lead to improved risk stratification and prognosis for patients with resectable PDAC.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.